Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 1051 to 1060 of 1090 total matches.
Safety of Terfenadine and Astemizole
The Medical Letter on Drugs and Therapeutics • Feb 07, 1992 (Issue 863)
Nizoral ketoconazole with terfenadine Interactions drug ...
Terfenadine (Seldane - Marion Merrell Dow) and astemizole (Hismanal - Janssen) are nonsedating antihistamines widely used to treat symptoms of allergic rhinitis (Medical Letter, 27:65, 1985; 31:43, 1989). Both are available without a prescription in Canada, and the US Food and Drug Administration is apparently considering terfenadine for over-the-counter availability in the USA.
Prevention of Pneumocystis Carinii Pneumonia
The Medical Letter on Drugs and Therapeutics • Oct 07, 1988 (Issue 776)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Pneumocystis carinii pneumonia (PCP) is a common cause of death in patients with acquired immune deficiency syndrome (AIDS). PCP is the first serious opportunistic infection in more than 60% of patients with AIDS, and about 80% of AIDS patients develop PCP at least once (AE Glatt et al, N Engl J Med, 318:1439, June 2, 1988). Many studies using drugs to prevent PCP in patients with AIDS have recently been reported.
Tislelizumab (Tevimbra) for Esophageal Cancer (online only)
The Medical Letter on Drugs and Therapeutics • May 13, 2024 (Issue 1702)
for second-line
treatment. All of these drugs can cause
significant toxicity.1,2
CLINICAL STUDIES ― FDA ...
The FDA has approved tislelizumab (Tevimbra –
BeiGene), a programmed death receptor-1 (PD-1)
blocking antibody, for treatment of unresectable
or metastatic esophageal squamous cell cancer in
adults who received prior systemic chemotherapy
that did not include a programmed death ligand-1
(PD-L1) inhibitor.
Med Lett Drugs Ther. 2024 May 13;66(1702):e85-6 doi:10.58347/tml.2024.1702h | Show Introduction Hide Introduction
Two New Amphetamines for ADHD
The Medical Letter on Drugs and Therapeutics • Jun 20, 2016 (Issue 1497)
The Medical Letter®
on Drugs and Therapeutics
Volume 58 (Issue 1497) June 20, 2016
Take CME ...
Two new extended-release amphetamine products
have been approved by the FDA for once-daily
treatment of attention-deficit/hyperactivity disorder
(ADHD) in patients ≥6 years old: Adzenys XR-ODT
(Neos Therapeutics), an orally distintegrating tablet,
and Dyanavel XR (Tris Pharma), an oral suspension.
Intravenous Ciprofloxacin
The Medical Letter on Drugs and Therapeutics • Aug 09, 1991 (Issue 850)
cyclosporine Fortaz Imipenem-cilastatin sodium Interactions drug with ciprofloxacin intravenous ...
Ciprofloxacin, previously available orally (Cipro - Medical Letter, 30:11, 1988) and for ophthalmic use (Ciloxan - Medical Letter, 33:52, May 31, 1991), is now the first fluoroquinolone antibiotic to become available in the USA in an intravenous (IV) formulation. Cipro I.V. (Miles) is being promoted as an alternative to third-generation cephalosporins, aminoglycosides, and other drugs used for treatment of serious infections.
Cefditoren (Spectracef) - A New Oral Cephalosporin
The Medical Letter on Drugs and Therapeutics • Jan 21, 2002 (Issue 1122)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Cefditoren pivoxil (Spectracef TAP), a new oral third-generation cephalosporin, has been approved by the FDA for treatment of acute exacerbations of chronic bronchitis, pharyngitis, tonsillitis and uncomplicated skin and soft tissue infections in adults and children 12 or more years old. The drug has been used in Japan for 7 years.
Fluoxetine For Depression
The Medical Letter on Drugs and Therapeutics • Apr 22, 1988 (Issue 764)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Fluoxetine (Prozac - Dista), a phenylpropylamide, is the first serotonin-reuptake blocker introduced in the USA for treatment of . It is being promoted as causing fewer adverse effects than other antidepressants. Claims of greater safety and patient tolerability have often been made for new non-tricyclic antidepressants in recent years, but unpredicted adverse effects have emerged with widespread use, including priapism with trazodone (Desyrel - Medical Letter, 26:35, 1984) and fatal hemolytic anemia with nomifensine (Merital - Medical Letter, 27:73, 1985).
Granisetron to Prevent Vomiting After Cancer Chemotherapy
The Medical Letter on Drugs and Therapeutics • Jul 08, 1994 (Issue 926)
affect the clearance of granisetron, but clinically relevant
interactions with other drugs ...
Granisetron, a serotonin (5-HT) antagonist similar to ondansetron, was recently approved by the US Food and Drug Administration for prevention of nausea and vomiting due to cancer chemotherapy. Although available in an oral formulation in other countries, granisetron is available here only for intravenous (IV) use.
Altuviiio – A Longer-Acting Factor VIII Product for Hemophilia A
The Medical Letter on Drugs and Therapeutics • May 01, 2023 (Issue 1675)
replacement therapy.
FACTOR VIII PRODUCTS ― The interaction between
factor VIII and VWF imposes a ceiling ...
The FDA has approved Altuviiio (Sanofi), a von
Willebrand Factor (VWF)-independent, recombinant
factor VIII concentrate, for routine prophylaxis, on-demand
treatment to control bleeding episodes, and
perioperative management of bleeding in children and
adults with hemophilia A. The manufacturer claims that
Altuviiio, which was previously called efanesoctocog
alfa, delivers normal to near-normal factor VIII levels for
most of the week with once-weekly intravenous dosing.
Med Lett Drugs Ther. 2023 May 1;65(1675):67-8 doi:10.58347/tml.2023.1675b | Show Introduction Hide Introduction
Toripalimab (Loqtorzi) for Nasopharyngeal Carcinoma (online only)
The Medical Letter on Drugs and Therapeutics • Jan 22, 2024 (Issue 1694)
receptors, blocking its interaction
with PD-L1 and PD-L2 and restoring T cell antitumor
immune responses ...
Toripalimab-tpzi (Loqtorzi – Coherus Biosciences),
a programmed death receptor-1 (PD-1)-blocking
antibody, has been approved by the FDA for use
in combination with cisplatin and gemcitabine for
first-line treatment of recurrent locally advanced or
metastatic nasopharyngeal carcinoma and for use as
monotherapy for treatment of recurrent unresectable
or metastatic nasopharyngeal carcinoma in adults
with disease progression on or after platinum-based
chemotherapy. It is the first immune checkpoint
inhibitor to be approved in the US for treatment of
nasopharyngeal carcinoma.
Med Lett Drugs Ther. 2024 Jan 22;66(1694):e16-7 doi:10.58347/tml.2024.1694e | Show Introduction Hide Introduction